Warning. Research only: not approved by the FDA for any use in people. Information is for scientific awareness only. Not a recommendation to use, buy or compound.
No perspectives yet — be the first!
Be the first verified clinician to share how you read the research on Ipamorelin.
100% anonymous · NPI-verifiedFDA status last checked Nov 11, 2026
A pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a ghrelin mimetic with growth hormone (GH) releasing activity. Ipamorelin mimics ghrelin and binds to the ghrelin receptor (or GH secretagogue receptor, GHSR) in the brain, thereby selectively stimulating the release of GH from the pituitary gland.
Ipamorelin
Not approved for use in people. Mostly lab or animal research.
Only small or early studies in people so far.
There is no FDA-approved product with this peptide.
How it works. Proven facts and ideas still being studied are kept apart.
Not yet reviewed.
Only small or early studies in people so far.
Not FDA-approved. Nominations withdrawn from FDA's 503A category 2 (significant safety risk) list in 2026. Still in category 2 (significant safety risk) for 503B outsourcing facilities. Not on the 503A bulks list.
Last verified: Nov 11, 2026
Scientific views only. No use in patients or dosing is discussed.
Share your scientific view of the published evidence on Ipamorelin.
Your view of the published research guides colleagues
Your name is never shown, only your specialty and region
About the published research. No use in patients or dosing
